FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379281269> ?p ?o ?g. }

• W4379281269 endingPage "10035" @default.
• W4379281269 startingPage "10035" @default.
• W4379281269 abstract "10035 Background: Despite major improvements in the survival of pediatric cancer patients that were achieved through the intensification of chemotherapy and the perfection of supportive care in the past decades, treatment outcomes for high-risk, relapsed, and refractory solid cancers remain unsatisfactory. Accelerating the progress of pediatric oncology requires both therapeutic advances and attention to reducing the long-term cytotoxic treatment-related side effects. This could be achieved by targeting specific molecular changes that drive pediatric malignancies. Methods: From September 2016 to August 2020, a total of 192 patients with pediatric high-risk solid tumors successfully underwent comprehensive genomic profiling. Since more than thirty patients had two or more biopsies from recurrent relapses, the total number of samples examined was 295. In the cohort, there were 78 cases of central nervous system tumors, 68 sarcomas, 14 neuroblastomas, 10 lymphomas, and 22 tumors of other histology. Whole-exome sequencing was performed in all patients, fusion gene analysis in 96% of patients, whole-transcriptome profiling in 84% of patients, and CNV analysis in 63% of patients. Results: The diagnostic yield of therapeutically actionable findings was 40%, with single-nucleotide variants and small insertions/deletions being the most common actionable alteration types. In 23% of patients, a clinically relevant gene fusion was identified. The majority of the identified fusions were of diagnostic significance, and 18% of those were therapeutically targetable gene fusions involving BRAF, RAF1, ALK, FGFR1, or NTRK2. Four patients were eligible for immunotherapy based on high tumor mutational burden ( > 10 mut/Mb). Lymphomas and CNS tumors showed the highest rate of patients with therapeutically actionable findings (60% and 56%, respectively), followed by neuroblastomas (36%), sarcomas (25%), and other solid tumors (23%). All results and individual treatment plans were discussed and approved at multidisciplinary molecular tumor boards. Conclusions: Precision medicine in pediatric oncology has rapidly developed over the last decade and resulted in new therapeutic options based on molecular biomarkers and increased our understanding of the complexity of pediatric malignancies. Supported by the Ministry of Health of the Czech Republic, grant nr. NU20-03-00240 and the project National Institute for Cancer Research (Programme EXCELES, ID Project No. LX22NPO5102) - Funded by the European Union - Next Generation EU." @default.
• W4379281269 created "2023-06-05" @default.
• W4379281269 creator A5077275682 @default.
• W4379281269 creator A5083291598 @default.
• W4379281269 creator A5088445118 @default.
• W4379281269 creator A5090036730 @default.
• W4379281269 creator A5090844895 @default.
• W4379281269 creator A5091536705 @default.
• W4379281269 date "2023-06-01" @default.
• W4379281269 modified "2023-10-09" @default.
• W4379281269 title "Comprehensive genomic profiling and individual therapeutic planning in high-risk/refractory pediatric solid tumors: A single-center real-world study." @default.
• W4379281269 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.10035" @default.
• W4379281269 hasPublicationYear "2023" @default.
• W4379281269 type Work @default.
• W4379281269 citedByCount "0" @default.
• W4379281269 crossrefType "journal-article" @default.
• W4379281269 hasAuthorship W4379281269A5077275682 @default.
• W4379281269 hasAuthorship W4379281269A5083291598 @default.
• W4379281269 hasAuthorship W4379281269A5088445118 @default.
• W4379281269 hasAuthorship W4379281269A5090036730 @default.
• W4379281269 hasAuthorship W4379281269A5090844895 @default.
• W4379281269 hasAuthorship W4379281269A5091536705 @default.
• W4379281269 hasConcept C104317684 @default.
• W4379281269 hasConcept C121608353 @default.
• W4379281269 hasConcept C126322002 @default.
• W4379281269 hasConcept C127716648 @default.
• W4379281269 hasConcept C143998085 @default.
• W4379281269 hasConcept C16671776 @default.
• W4379281269 hasConcept C185592680 @default.
• W4379281269 hasConcept C2776694085 @default.
• W4379281269 hasConcept C2781230642 @default.
• W4379281269 hasConcept C55493867 @default.
• W4379281269 hasConcept C71924100 @default.
• W4379281269 hasConceptScore W4379281269C104317684 @default.
• W4379281269 hasConceptScore W4379281269C121608353 @default.
• W4379281269 hasConceptScore W4379281269C126322002 @default.
• W4379281269 hasConceptScore W4379281269C127716648 @default.
• W4379281269 hasConceptScore W4379281269C143998085 @default.
• W4379281269 hasConceptScore W4379281269C16671776 @default.
• W4379281269 hasConceptScore W4379281269C185592680 @default.
• W4379281269 hasConceptScore W4379281269C2776694085 @default.
• W4379281269 hasConceptScore W4379281269C2781230642 @default.
• W4379281269 hasConceptScore W4379281269C55493867 @default.
• W4379281269 hasConceptScore W4379281269C71924100 @default.
• W4379281269 hasIssue "16_suppl" @default.
• W4379281269 hasLocation W43792812691 @default.
• W4379281269 hasOpenAccess W4379281269 @default.
• W4379281269 hasPrimaryLocation W43792812691 @default.
• W4379281269 hasRelatedWork W2316766300 @default.
• W4379281269 hasRelatedWork W2321734596 @default.
• W4379281269 hasRelatedWork W2328465541 @default.
• W4379281269 hasRelatedWork W2371666691 @default.
• W4379281269 hasRelatedWork W2378355431 @default.
• W4379281269 hasRelatedWork W2378490490 @default.
• W4379281269 hasRelatedWork W2387957804 @default.
• W4379281269 hasRelatedWork W2741866105 @default.
• W4379281269 hasRelatedWork W3140477201 @default.
• W4379281269 hasRelatedWork W95026785 @default.
• W4379281269 hasVolume "41" @default.
• W4379281269 isParatext "false" @default.
• W4379281269 isRetracted "false" @default.
• W4379281269 workType "article" @default.